SCHEMBL167489

SCHEMBL167489

CN(C)C1(N(C)C)CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
SLC6A3 Q01959 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25137307 0.96 SLC6A2 (0.30) SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL7213348 0.93
SCHEMBL3469334 0.76 ADH1C (0.33)
SCHEMBL23699777 0.69 SLC6A2 (0.30) SLC6A2SLC6A4SLC6A3
SCHEMBL171561 0.69 SLC6A4 (0.32) SLC6A2SLC6A4SLC6A3
SCHEMBL1889080 0.69 SLC6A4 (0.32) SLC6A2SLC6A4SLC6A3
SCHEMBL25137314 0.67 SLC6A4 (0.44) SLC6A2SLC6A4SLC6A3
SCHEMBL1929358 0.67 SLC6A2 (0.31) SLC6A2SLC6A4SLC6A3
SCHEMBL20752517 0.67 SLC6A2 (0.31) SLC6A2SLC6A4SLC6A3
SCHEMBL304273 0.67 SLC6A2 (0.31) SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516504-A1 BIODEGRADABLE POLYMERS, COMPLEXES THEREOF FOR GENE THERAPEUTICS AND DRUG DELIVERY, AND METHODS RELATED THERETO International Business Machines Corporation (US) 2012-10-31 EP claimed
WO-2011078805-A1 BIODEGRADABLE POLYMERS, COMPLEXES THEREOF FOR GENE THERAPEUTICS AND DRUG DELIVERY, AND METHODS RELATED THERETO INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2011-06-30 WO claimed
EP-1363923-B1 RHODIUM AND IRIDIUM COMPLEXES MERCK PATENT GMBH (DE) 2009-04-01 EP claimed
US-7414133-B2 Palladium and platinum complexes MERCK PATENT GMBH 2008-08-19 US claimed
US-7125998-B2 Rhodium and iridium complexes MERCK PATENT GMBH (DE) 2006-10-24 US claimed
EP-1562964-B1 PALLADIUM AND PLATINUM COMPLEXES MERCK PATENT GMBH (DE) 2006-07-19 EP claimed
EP-1363923-A1 RHODIUM AND IRIDIUM COMPLEXES Covion Organic Semiconductors GmbH (DE) 2003-11-26 EP claimed
WO-2002068435-A1 RHODIUM AND IRIDIUM COMPLEXES COVION ORGANIC SEMICONDUCTORS GMBH (DE) 2002-09-06 WO claimed
US-12612313-B2 Method for producing lithium halide compound IDEMITSU KOSAN CO., LTD. (JP) 2026-04-28 US disclosed
US-20260008676-A1 METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE IDEMITSU KOSAN CO.,LTD. (JP) 2026-01-08 US disclosed
US-20250372697-A1 METHOD FOR PRODUCING SOLID ELECTROLYTE, AND ELECTROLYTE PRECURSOR IDEMITSU KOSAN CO.,LTD. (JP) 2025-12-04 US disclosed
EP-4657469-A1 METHOD FOR PRODUCING SULFIDE SOLID ELECTROLYTE Idemitsu Kosan Co.,Ltd. (JP) 2025-12-03 EP disclosed
EP-4159678-B1 METHOD FOR PRODUCING LITHIUM HALIDE COMPOUND IDEMITSU KOSAN CO (JP) 2025-10-01 EP disclosed
US-12381253-B2 Solid electrolyte containing a thio-lisicon region II crystal structure IDEMITSU KOSAN CO., LTD. (JP) 2025-08-05 US disclosed
US-6492558-B2 PREPARATION OF N-BUTYLAMINES FROM N-BUTENYLAMINES WHICH ARE ARE PREPARED BY REACTING 1,3-BUTADIENE IN THE FORM OF A 1,3-BUTADIENE-CONTAINING MIXTURE OBTAINED DURING THE CRACKING OF PETROLEUM FRACTIONS BASF AKTIENGESELLSCHAFT (DE) 2002-12-10 US disclosed
US-20020169319-A1 Preparation of n-butylamines BASF AKTIENGESELLSCHAFT (DE) 2002-11-14 US disclosed
EP-1238964-A1 Process for preparing n-butylamines and n-butenylamines BASF AKTIENGESELLSCHAFT (DE) 2002-09-11 EP disclosed
WO-2002068435-A1 RHODIUM AND IRIDIUM COMPLEXES COVION ORGANIC SEMICONDUCTORS GMBH (DE) 2002-09-06 WO disclosed
US-4268455-A Chelating tertiary amino metal amides EXXON RESEARCH & ENGINEERING CO. (US) 1981-05-19 US disclosed
US-4165330-A REACTION OF ORGANOLITHIUM-CHELATE COMPLEX AND PROCHIRAL UNSATURATED CARBONYL COMPOUNDS EXXON RESEARCH & ENGINEERING CO. (US) 1979-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008676-A1 METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE CACNA1S, CACNA1A, VRK2 SLC6A2 1029/4885SLC6A4 417/4885SLC6A3 234/4885
US-12612313-B2 Method for producing lithium halide compound CLCN2, SLC6A12, CLIC1 SLC6A2 1832/4885SLC6A4 1556/4885SLC6A3 419/4885
US-20020169319-A1 Preparation of n-butylamines HNMT, PNMT, LIPG SLC6A2 787/4885SLC6A4 1311/4885SLC6A3 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.